BioAge Labs, Inc. (BIOA)
5.87
-0.07
(-1.18%)
USD |
NASDAQ |
Oct 30, 16:00
5.90
+0.03
(+0.51%)
After-Hours: 20:00
BioAge Labs Enterprise Value : -47.20M for Oct. 30, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 30, 2026 | -47.20M |
| October 29, 2026 | -44.00M |
| October 28, 2026 | -44.00M |
| October 27, 2026 | -65.51M |
| October 26, 2026 | -87.48M |
| October 23, 2026 | -82.45M |
| October 22, 2026 | -62.76M |
| October 21, 2026 | -63.68M |
| October 20, 2026 | -61.39M |
| October 19, 2026 | -87.48M |
| October 16, 2026 | -94.35M |
| October 15, 2026 | -71.00M |
| October 14, 2026 | -67.80M |
| October 13, 2026 | -60.93M |
| October 12, 2026 | -44.00M |
| October 09, 2026 | -25.68M |
| October 08, 2026 | -31.64M |
| October 07, 2026 | -29.35M |
| October 06, 2026 | -27.97M |
| October 05, 2026 | -24.77M |
| October 02, 2026 | -13.32M |
| October 01, 2026 | -4.169M |
| September 30, 2026 | 8.648M |
| September 29, 2026 | 10.94M |
| September 28, 2026 | 12.77M |
| Date | Value |
|---|---|
| September 25, 2026 | 6.817M |
| September 24, 2026 | 14.14M |
| September 23, 2026 | 45.27M |
| September 22, 2026 | 71.36M |
| September 21, 2026 | 54.43M |
| September 18, 2026 | 53.05M |
| September 17, 2026 | 54.43M |
| September 16, 2026 | 38.86M |
| September 15, 2026 | 58.54M |
| September 14, 2026 | 72.28M |
| September 11, 2026 | 72.74M |
| September 10, 2026 | 80.06M |
| September 09, 2026 | 103.86M |
| September 08, 2026 | 114.16M |
| September 04, 2026 | 123.09M |
| September 03, 2026 | 118.97M |
| September 02, 2026 | 129.50M |
| September 01, 2026 | 119.89M |
| August 31, 2026 | 118.97M |
| August 28, 2026 | 125.84M |
| August 27, 2026 | 145.52M |
| August 26, 2026 | 134.53M |
| August 25, 2026 | 146.89M |
| August 24, 2026 | 113.48M |
| August 21, 2026 | 118.06M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Neumora Therapeutics, Inc. | 5.030M |
| Alumis, Inc. | 398.98M |
| ANI Pharmaceuticals, Inc. | 1.889B |
| Corcept Therapeutics, Inc. | 8.456B |
| Veru, Inc. | 14.23M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.10M |
| Revenue (Quarterly) | 2.451M |
| Total Expenses (Quarterly) | 28.55M |
| EPS Diluted (Quarterly) | -0.582 |
| Gross Profit Margin (Quarterly) | 97.14% |
| Profit Margin (Quarterly) | -1.06K% |
| Earnings Yield | -40.66% |
| Normalized Earnings Yield | -40.49 |